In September, 2015, Endo International plc (NASDAQ: ENDP) (TSX: ENDP) acquired Par Pharmaceutical merging the business with Endo's Qualitest, thereby expanding the generics business to a top five industry leader.
Endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through its operating companies. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, PA.
» Par Pharmaceutical - Founded in 1978, today the company's sales place it among the leading generic pharmaceutical companies in the United States.*
» Employs approximately 3,700 professionals in offices in Chestnut Ridge, New York; Irvine, California; Rochester, Michigan; Stratford, Connecticut; Chennai, India ; Montebello, New York and Huntsville, Alabama.
» An experienced Authorized Generics partner of choice for many of the world's leading pharmaceutical companies.
» Conducts manufacturing in the United States and abroad and markets and/or license more than 200 prescriptions drug products families.
» Strong distribution relationships in place at top U.S. retail chains, wholesalers, distributors, managed care organizations, mail order pharmacies and group purchasing organizations.
» Operational excellence in quality and compliance.
*for the year ending 2015. source :IMS Health.